newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the